EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study

Yan Le, Wenlin Yang, Jianyun Lu, Xian Jiang iD, Qing Guo, Chunyun Huang, Qing Sun, Huiping Wang, Mingye Bi, Haiying Wang, Songmei Geng, Bin Yang und 20 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20159 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Yan Le und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acne Vulgaris, Minocycline, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Cutia Therapeutics (Shanghai) Co., Ltd, Shanghai, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

FMX101 4%, as a topical foam formulation of minocycline, has been approved by US Food and Drug Administration for the treatment of moderate‐to‐severe acne vulgaris (AV).

Objective

To evaluate the efficacy and safety of FMX101 4% in treating Chinese subjects with moderate‐to‐severe facial AV.

Methods

This was a multi‐centre, randomized, double‐blind, vehicle‐controlled phase 3 study in Chinese subjects with moderate‐to‐severe AV. Eligible subjects were randomized 2:1 to receive either FMX101 4% or vehicle foam treatment for 12 weeks. The primary efficacy endpoint was the change in inflammation lesion count (ILC) from baseline at week 12. The key secondary endpoint was the treatment success rate according to Investigator's Global Assessment (IGA) at week 12.

Results

In total, 372 subjects were randomized into two groups (FMX101 4% group, n = 248; vehicle group, n = 124). After 12 weeks treatment, the reduction in ILC from baseline was statistically significant in favour of FMX101 4%, compared with vehicle foam (−21.0 [0.08] vs. −12.3 [1.14]; LSM [SE] difference, −8.7 [1.34]; 95% CI [−11.3, −6.0]; p < 0.001). FMX101 4% treatment yielded significantly higher IGA treatment success rate at week 12 as compared to the control treatment (8.06% vs. 0%). Applying FMX101 4% also resulted in significant reduction in noninflammatory lesion count (nILC) versus vehicle foam at week 12 (−19.4 [1.03] vs. −14.9 [1.47]; LSM [SE] difference, −4.5 [1.74]; 95% CI [−8.0, −1.1]; p = 0.009). Most treatment‐emergent adverse events (TEAEs) were mild‐to‐moderate in severity, and no treatment‐related treatment‐emergent serious adverse event (TESAE) occurred. Thus, FMX101 4% was considered to be a safe and well‐tolerated product during the 12‐week treatment period.

Conclusions

FMX101 4% treatment for 12 weeks could lead to significantly reduced ILC and nILC, and improved IGA treatment success rate in Chinese subjects with moderate‐to‐severe facial AV. It also showed a well acceptable safe and tolerability profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisMinocyclineAnti-Bacterial AgentsHumansDouble-Blind MethodFemaleMaleAdultYoung AdultSeverity of Illness IndexTreatment OutcomeAdolescentChinaFaceAdministration, TopicalEast Asian People

Substanzen

MinocyclineAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Dermatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Dermatovenereology, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Dermatology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Dermatology, Qilu Hospital of Shandong University, Jinan, China.

ORCID-Profile: Xian Jiang, Yong Cui, Xiaoyong Man, Leihong Xiang

Förderung

  • Cutia Therapeutics (Shanghai) Co., Ltd, Shanghai, China

Zitieren

APA

Le, Y., Yang, W., Lu, J., Jiang, X., Guo, Q., Huang, C., Sun, Q., Wang, H., Bi, M., Wang, H., Geng, S., Yang, B., Xu, A. E., Cui, Y., Man, X., Zhao, Y., Zhang, L., Li, L., Song, Z., …, & Xiang, L. (2025). Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20159

Vancouver

Le Y, Yang W, Lu J, Jiang X, Guo Q, Huang C, et al. Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20159

BibTeX
@article{Le2025,
  author = {Le, Yan and Yang, Wenlin and Lu, Jianyun and Jiang, Xian and Guo, Qing and Huang, Chunyun and Sun, Qing and Wang, Huiping and Bi, Mingye and Wang, Haiying and Geng, Songmei and Yang, Bin and Xu, Ai-E and Cui, Yong and Man, Xiaoyong and Zhao, Yi and Zhang, Litao and Li, Linfeng and Song, Zhiqiang and Chen, Jin and Cheng, Hao and Zhu, Wei and Han, Xiuping and Li, Shanshan and Lin, Tong and Zhang, Chunlei and Li, Jiuhong and Li, Yanling and Ding, Yangfeng and Wang, Linda and Zhu, Yuefang and Xiang, Leihong},
  title = {Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20159}
}
Kostenlos starten →